AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4074113
Drug: Therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy group (including insight-oriented and current events)
Trial: 28116430
Drug: Essential periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Essential periodontal treatment + routine maintenance therapy (Group A)
Trial: 28116430
Drug: Routine maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine maintenance therapy (Group B)
Trial: 28116430
Drug: Essential periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Essential periodontal treatment (Group C)
Trial: 22938760
Drug: Oral antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic treatment
Trial: 1337708
Drug: Estraderm TTS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estraderm TTS, a 17 beta‐estradiol, administered for 11 weeks (3 cycles of 3 weeks treatment followed by 1 week therapy-free)
Trial: 1337708
Drug: Premarin, consisting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin, consisting of conjugated estrogens, administered for 11 weeks (3 cycles of 3 weeks treatment followed by 1 week therapy-free)
Trial: 3090962
Drug: Urokinase 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase 2000 U/kg/h for 24 hours with heparin (Group I: 18 patients)
Trial: 3090962
Drug: Urokinase 4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase 4500 U/kg/h for 12 hours without heparin (Group II: 47 patients)
Trial: 3090962
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose urokinase group (Group II)
Trial: 24861836
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy (one-time intervention)
Trial: 19841157
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium gel 1% (16 g gel applied as 4 g to 1 knee 4 times daily)
Trial: 19841157
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium gel 1% (48 g gel applied as 4 g per knee 4 times daily to 2 knees plus 2 g gel per hand applied 4 times daily to 2 hands)
Trial: 19841157
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac sodium (150 mg oral diclofenac applied as 50-mg tablets 3 times daily)
Trial: 19841157
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium gel 1%
Trial: 19841157
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac sodium
Trial: 17658120
Drug: Proprietary fractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary fractionated white bean extract (1000 mg, twice a day before meals)
Trial: 11048457
Drug: ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (8 mg in 4 mL i.v.)
Trial: 11048457
Drug: placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (4 mL saline i.v.)
Trial: 8750569
Drug: Diltiazem, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 60 mg twice a day for 30 days
Trial: 8750569
Drug: Diltiazem with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem with propylthiouracil, 100 mg three times a day for the last 20 days
Trial: 4008675
Drug: Pramiracetam 400
RxNorm normalized name: aniracetam
DrugBank: Aniracetam (DB04599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiracetam 400 mg
Trial: 4008675
Drug: Pramiracetam 800
RxNorm normalized name: piracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiracetam 800 mg
Trial: 4008675
Drug: Pramiracetam 1200
RxNorm normalized name: piracetam 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiracetam 1200 mg
Trial: 4008675
Drug: Pramiracetam 1600
RxNorm normalized name: aniracetam
DrugBank: Aniracetam (DB04599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiracetam 1600 mg
Trial: 30582717
Drug: Calcipotriol (50 μg/g)
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam
Trial: 30582717
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% cream
Trial: 30582717
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% cream
Trial: 30582717
Drug: Hydrocortisone-17-butyrate 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone-17-butyrate 0.1% ointment
Trial: 19092238
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin infusion (50 IU insulin in 50 ml 0.9% saline solution applied intravenously via a perfusor pump)
Trial: 19092238
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (insulin subcutaneously if concentrations were above 11.10 mmol/l)
Trial: 12630984
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg once daily for 9 days
Trial: 3504725
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection of synthetic salmon calcitonin (SSCT) 80 IU
Trial: 29384933
Drug: Video laryngoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video laryngoscopic guidance in the left lateral position (Group L)
Trial: 20853007
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone for 10 days followed by oral cephalexin for 3 months (Control)
Trial: 18367613
Drug: Chronic prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic prednisone treatment (7.5 +/- 0.8 mg)
Trial: 18367613
Drug: Acute prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute prednisone administration 1 hour before retention testing
Trial: 9176834
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zinc
Trial: 9176834
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zinc with micronutrients
Trial: 9176834
Drug: Zinc-containing treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc-containing treatments
Trial: 2481787
Drug: Mepindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol (10 mg/day)
Trial: 2481787
Drug: Celiprolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (400 mg/day)
Trial: 25795285
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (2.5 g twice daily)
Trial: 19201289
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily)
Trial: 17317362
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day of atorvastatin for 16 weeks
Trial: 28886437
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg apple polyphenols (AE)
Trial: 28886437
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg apple polyphenols + 600 mg blackcurrant anthocyanins (AE+BE)
Trial: 26635453
Drug: Topical 0.02%
RxNorm normalized name: tretinoin topical 0.02% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.02% mitomycin C four times a day for five days
Trial: 26635453
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% cyclosporine four times a day for three months
Trial: 26635453
Drug: Topical 2.5%
RxNorm normalized name: menthol topical 2.5% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2.5% bevacizumab four times a day for three months
Trial: 23466591
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate 5 g daily
Trial: 17056383
Drug: Subconjunctival lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival lidocaine 2% injection
Trial: 10867305
Drug: Immediate, rent-free,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate, rent-free, abstinent-contingent housing during a 2-month Behavioral Day Treatment program
Trial: 10867305
Drug: Behavioral Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Day Treatment attendance
Trial: 1703237
Drug: Flavone acetic
RxNorm normalized name: flavone
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavone acetic acid at doses less than or equal to 3.9 g/m2 administered intravenously over 1 hour
Trial: 1703237
Drug: Flavone acetic
RxNorm normalized name: flavone
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavone acetic acid at doses greater than or equal to 5.28 g/m2 administered over 6 hours
Trial: 1703237
Drug: Flavone acetic
RxNorm normalized name: flavone
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavone acetic acid at 10 g/m2
Trial: 1703237
Drug: Flavone acetic
RxNorm normalized name: flavone
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavone acetic acid at 8 g/m2 recommended for phase II
Trial: 6867755
Drug: Sequential MTX/5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MTX/5‐FU
Trial: 6867755
Drug: Sequential 5‐FU/MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential 5‐FU/MTX
Trial: 26813483
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavioral therapy (CBT) delivered via email, 10 to 12 sessions conducted by a psychiatrist and a psychiatry resident.
Trial: 24352960
Drug: DDGS at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDGS at 0.5% of BW daily (DM basis)
Trial: 24352960
Drug: DDGS at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDGS at 1% of BW daily (DM basis)
Trial: 21978965
Drug: Celivarone 300
RxNorm normalized name: Celivarone
DrugBank: Celivarone (DB16012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celivarone 300 mg once daily for 6 months
Trial: 21978965
Drug: Celivarone 300
RxNorm normalized name: Celivarone
DrugBank: Celivarone (DB16012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celivarone 300 mg once daily for 6 months (subgroup analysis)
Trial: 20451927
Drug: Pramipexole 0.25-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.25-0.75 mg/day
Trial: 18046434
Drug: Perindopril (ACE-inhibitor)
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril (ACE-inhibitor)
Trial: 12444517
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment (15 days strapping plus early controlled mobilization)
Trial: 2344111
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient treatment program
Trial: 2344111
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient treatment program (after crossover)
Trial: 6424491
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate aerosol (2 mg four times daily)
Trial: 6424491
Drug: Conventional powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional powder (20 mg four times daily by Spinhaler)
Trial: 28872672
Drug: Business as
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Business as usual treatment
Trial: 29950252
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 10 mg once weekly for eight weeks
Trial: 29950252
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids 40 mg daily for eight weeks, then tapered
Trial: 24092823
Drug: Preoperative octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative octreotide treatment (n=28)
Trial: 24092823
Drug: Octreotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide treatment for 6 months
Trial: 17882161
Drug: Laropiprant (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant (single doses up to 900 mg)
Trial: 17882161
Drug: Laropiprant (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant (multiple doses up to 450 mg)
Trial: 17882161
Drug: Laropiprant (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant (single doses of 6 mg and higher)
Trial: 17882161
Drug: Laropiprant (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant (multiple doses up to 200 mg)
Trial: 10440427
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg tablet)
Trial: 10440427
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg capsule)
Trial: 8680375
Drug: Inhaled bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bradykinin (8 mg.mL‐1)
Trial: 8680375
Drug: Inhaled [desArg9]-bradykinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled [desArg9]-bradykinin (8 mg.mL‐1)
Trial: 26842107
Drug: Mirtazapine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (starting at 15 mg daily for 2 weeks, increasing to 30 mg daily thereafter, for up to 12 months)
Trial: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MXD) 0.2 mg/kg SC
Trial: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MXD) 1.0 mg/kg SC
Trial: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MXD) 0.2 mg/kg IR
Trial: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MXD) 1.0 mg/kg IR
Trial: 30736951
Drug: Ivermectin (IVM)
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin (IVM) 0.2 mg/kg SC
Trial: 20191820
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) therapy
Trial: 16669847
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg twice daily for 5 days)
Trial: 16669847
Drug: Diltiazem (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (100 mg twice daily for 5 days)
Trial: 12525736
Drug: Thalidomide (TL)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide (TL) at doses up to 200 mg/d
Trial: 1425819
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with bromocriptine and levodopa
Trial: 3939673
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg bid)
Trial: 22652593
Drug: G-CSF 10
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF 10 μg/kg per day intravenously for 5 consecutive days
Trial: 22652593
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar treatments without G-CSF)
Trial: 20028939
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diazoxide at bedtime
Trial: 18541589
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (3 g CaCO3 daily, providing 1200 mg elemental Ca)
Trial: 11032056
Drug: Dithranol cream
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dithranol cream
Trial: 8421798
Drug: DDAVP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP infusion (0.3 microliter per kilogram) during 15 to 30 minutes within one hour of anesthetic induction
Trial: 2430084
Drug: 7S immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Trial: 2430084
Drug: 5S immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Trial: 18417741
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 10,000 IU once weekly
Trial: 16184544
Drug: Basiliximab 20
RxNorm normalized name: basiliximab 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab 20 mg on days 0 and 4; tacrolimus delayed until renal function improved
Trial: 25190617
Drug: Tailored duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored duration of ECS therapy following an initial therapeutic period of 6 months
Trial: 25190617
Drug: Standard duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard duration of ECS therapy for 24 months
Trial: 22242967
Drug: Febuxostat 120
RxNorm normalized name: Febuxostat 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 120 mg daily for 9 days (regimen A)
Trial: 19464001
Drug: P(4) +
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P(4) + oral E(2) valerate
Trial: 7953888
Drug: G‐CSF and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF and Gm‐CSF
Trial: 29154814
Drug: Aquarobic exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquarobic exercise and burdock intake combination
Trial: 14504313
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with PE followed by IVIg or immunoabsorption followed by IVIg
Trial: 24355450
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (monthly videoconferences with a nurse for 32 weeks)
Trial: 22335087
Drug: Height and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Height and weight adjusted dose of intrathecal hyperbaric bupivacaine (Group AD)
Trial: 22335087
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of intrathecal hyperbaric bupivacaine (2.2 ml) (Group FD)
Trial: 22335087
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of intrathecal hyperbaric bupivacaine (Group FD)
Trial: 16895948
Drug: Perioperative hyperinsulinemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative hyperinsulinemic normoglycemic clamp (regular insulin at a fixed rate of 0.1 IU.kg(‐1).h(‐1)) during 26 hours
Trial: 14745701
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of ill index cases with oseltamivir for 5 days (n=402)
Trial: 11355938
Drug: CA 125
RxNorm normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 125 monitoring during first-line chemotherapy
Trial: 8133020
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g DGLA
Trial: 8133020
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g safflower oil
Trial: 23347793
Drug: pegaptanib injection
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegaptanib injection
Trial: 21629200
Drug: Liquid L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid L-carnitine (50 mg L-carnitine/kg bodyweight/day) for 3 months
Trial: 20144362
Drug: Levemir (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levemir (insulin detemir) FlexPen
Trial: 20144362
Drug: OptiClik (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiClik (insulin glargine)
Trial: 17723076
Drug: S-albuterol 5
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-albuterol 5 mg